Carotid ArteriosclerosisRECEPTNCT07057297
Residual Stenosis and Restenosis Following Carotid Endarterectomy With Primary Closure, A Prospective Tracking Study
An observational study of Carotid Arteriosclerosis and Carotid Stenosis, run by Charles University, Czech Republic at 1 site in Czechia.
Trial summary
This prospective, multicenter observational study aims to evaluate the incidence, timing, and characteristics of residual and recurrent (restenosis) carotid artery stenosis following carotid endarterectomy (CEA) with primary closure. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Carotid Arteriosclerosis, Carotid Stenosis, Brain Stroke
- How many people
- 300 participants
- Where
- 1 siteCzechia
- Study dates
- 1 Feb 2025to 1 Jan 2027
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients who undergo carotid endarterectomy for carotid artery stenosis with primary suture.
Who may be able to join
- Patients without matching any of exclusion criteria who underwent cartotid endarterectomy
Who cannot join
- Age ≤18 or ≥90 years
- Previous endarterectomy or stenting
- Unsuitable vascular anatomy
- High perioperative risk
- Contralateral cranial nerve X or XII palsy
- History of neck irradiation
- Tandem carotid stenosis or intracranial vascular pathology (e.g., aneurysm or AVM)
- Absence of signed informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Czechia1 site, 1 recruiting
- Recruiting
Central Military Hospital Prague
Prague, 16200
Norbert Svoboda, MD, +420973202963, norbert.svoboda@uvn.cz
David Netuka, Prof., ++420973202963, david.netuka@uvn.cz
About this study
This prospective, multicenter observational study aims to evaluate the incidence, timing, and characteristics of residual and recurrent (restenosis) carotid artery stenosis following carotid endarterectomy (CEA) with primary closure. Conducted across several neurosurgical centers in the Czech Republic, the study will include patients undergoing elective CEA who meet standard clinical indications.
Participants will undergo preoperative CT angiography and follow-up imaging at 30 days and 1 year post-surgery. Residual stenosis is defined as ≥50% luminal narrowing detected within 30 days postoperatively, while restenosis is evaluated at later time points. The study will also assess clinical outcomes such as ischemic stroke, TIA, myocardial infarction, and mortality. The standardized surgical technique and harmonized diagnostic algorithm across all centers aim to provide robust data on the performance and durability of primary closure CEA.
Read the detailed description
Study Objective:
The objective of this study is to assess the true incidence of restenosis following CEA in the Czech Republic. A major advantage of this study is the use of standardized surgical procedures across participating centers, along with unified data collection methods and diagnostic algorithms.
Methodology:
Patient Cohort:
All patients meeting the current guideline indications for CEA will be enrolled.
Exclusion criteria include:
Age ≤18 or ≥90 years
Previous endarterectomy or stenting
Unsuitable vascular anatomy
High perioperative risk
Contralateral cranial nerve X or XII palsy
History of neck irradiation
Tandem carotid stenosis or intracranial vascular pathology (e.g., aneurysm or AVM)
Absence of signed informed consent
Collected data will include:
Epidemiologic risk factors: age, sex, diabetes, hypertension, dyslipidemia, metabolic syndrome, renal insufficiency, smoking, physical activity, weight, comorbidities
Laboratory markers: LDL, HDL, cholesterol, lipoprotein A, triglycerides, CKD-EPI, sedimentation rate, fibrinogen, INR (Quick test), APTT
Diagnostics:
All patients will undergo non-contrast brain CT. Carotid stenosis will be assessed by CT angiography performed within 3 months prior to surgery. In addition to stenosis severity, the degree of calcification will be classified as:
No calcification
Minimal
Partially calcified
Pronounced
Severe/unable to evaluate
Other vascular pathology will also be recorded. Follow-up imaging will be performed at 1 month and 1 year postoperatively. CT findings will be assessed by two independent reviewers.
Surgical Technique:
All patients will receive mono- or dual antiplatelet therapy, and 5,000 IU of heparin will be administered intraoperatively. Surgery may be performed under general anesthesia with electrophysiological monitoring or under local anesthesia, based on the surgeon's preference.
A longitudinal incision will be made anterior to the sternocleidomastoid muscle. The common carotid artery and its branches will be dissected and clamped. The internal carotid artery will be clamped distal to the most significant stenosis, as identified on preoperative CTA. The surgeon will incise through the tunica adventitia and media to expose and excise the atherosclerotic plaque. Any residual fragments will be removed, and the arterial wall will be closed using 6/0 suture.
Follow-Up:
Patients will continue on mono- or dual antiplatelet therapy. Mandatory follow-up CT angiography will be performed at 30 days and1 year. During follow-up, the following will be evaluated:
CTA findings
Overall patient condition
Incidence of ischemic stroke (iCMP), TIA, myocardial infarction, and death
Outcomes:
Primary Outcome:
Restenosis ≥50% at 12 months
Secondary Outcomes:
Residual stenosis ≥50% at 30 days
iCMP/TIA/death/MI
Change in modified Rankin Scale (mRS)
Timeline:
All participating centers (ÚVN, ČB, ÚNL, Poruba, Plzeň, Liberec, Zlín, Olomouc, Hradec Králové, Fifejdy, Ostrava) together treat approximately 600-700 patients annually.
An estimated 350 patients will be enrolled within 6 months. By the end of 2026, 300 patients will be included (expected dropout: 50).
This will allow evaluation of:
Secondary outcomes in all 300 patients
Primary outcome in approximately 8 out of 26 centers (those with complete 12-month data)
Ethical Approval:
All participating centers have received approval from their respective institutional ethics committees.
Funding:
This study is conducted without external financial support.
- Conditions
- Carotid Arteriosclerosis, Carotid Stenosis, Brain Stroke
- Keywords
- Carotid Artery, Atherosclerosis, Endarterectomy, Stroke
- Medical subject headings
- Carotid Artery Diseases, Carotid Stenosis, Atherosclerosis, Stroke
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients after carotid endarterectomy | Included paitnets with sign informed consent after carotid endarterectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Restenosis ≥50% at 12 months
Restenosis ≥50% at 12 months
Measured: 12 months
Secondary outcomes (3)
Restenosis ≥50%
Restenosis ≥50%
Measured: 30 days
iCMP/TIA/death/MI
iCMP/TIA/death/MI
Measured: 1 year
Change in modified Rankin Scale (mRS)
Change in modified Rankin Scale (mRS)
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2025
- Study start1 Feb 2025
- Primary completion1 Jan 2026 (estimated)
- Study completion1 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Carotid ArteriosclerosisStudies of the same condition, open and under way.
- More trials run by Charles University, Czech RepublicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Charles University, Czech Republic
- Sponsor type
- University, hospital or other
- Collaborators
- The University Hospital Plzeň, Masaryk Hospital Usti nad Labem, University Hospital Olomouc, County Hospital Liberec, Liberec, Czech Republic
- Responsible party
- Principal investigator, Norbert Svoboda, Charles University, Czech Republic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07057297
- Sponsor's protocol ID
- 108/19-31/2024
- Acronym
- RECEPT
- Status last verified
- Jun 2025
- First submitted
- 30 Jun 2025
- Last updated
- 9 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Epidemiologic risk factors: age, sex, diabetes, hypertension, dyslipidemia, metabolic syndrome, renal insufficiency, smoking, physical activity, weight, comorbidities Laboratory markers: LDL, HDL, cholesterol, lipoprotein A, triglycerides, CKD-EPI, sedimentation rate, fibrinogen, INR (Quick test), APTT
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Residual Stenosis and Restenosis Following Carotid Endarterectomy With Primary Closure, A Prospective Tracking Study
- ClinicalTrials.gov ID
- NCT07057297
- Acronym / sponsor ID
- RECEPT / 108/19-31/2024
- Conditions
- Carotid Arteriosclerosis, Carotid Stenosis, Brain Stroke
- Keywords
- Carotid Artery, Atherosclerosis, Endarterectomy, Stroke
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Charles University, Czech RepublicUniversity, hospital or other
- Collaborators
- The University Hospital Plzeň, Masaryk Hospital Usti nad Labem, University Hospital Olomouc, County Hospital Liberec, Liberec, Czech Republic
- Study start
- 1 Feb 2025 (actual)
- Primary completion
- 1 Jan 2026 (estimated)
- Study completion
- 1 Jan 2027 (estimated)
- First posted
- 9 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective, multicenter observational study aims to evaluate the incidence, timing, and characteristics of residual and recurrent (restenosis) carotid artery stenosis following carotid endarterectomy (CEA) with primary closure. Conducted across several neurosurgical centers in the Czech Republic, the study will include patients undergoing elective CEA who meet standard clinical indications.
Participants will undergo preoperative CT angiography and follow-up imaging at 30 days and 1 year post-surgery. Residual stenosis is defined as ≥50% luminal narrowing detected within 30 days postoperatively, while restenosis is evaluated at later time points. The study will also assess clinical outcomes such as ischemic stroke, TIA, myocardial infarction, and mortality. The standardized surgical technique and harmonized diagnostic algorithm across all centers aim to provide robust data on the performance and durability of primary closure CEA.
Detailed description
Study Objective:
The objective of this study is to assess the true incidence of restenosis following CEA in the Czech Republic. A major advantage of this study is the use of standardized surgical procedures across participating centers, along with unified data collection methods and diagnostic algorithms.
Methodology:
Patient Cohort:
All patients meeting the current guideline indications for CEA will be enrolled.
Exclusion criteria include:
Age ≤18 or ≥90 years
Previous endarterectomy or stenting
Unsuitable vascular anatomy
High perioperative risk
Contralateral cranial nerve X or XII palsy
History of neck irradiation
Tandem carotid stenosis or intracranial vascular pathology (e.g., aneurysm or AVM)
Absence of signed informed consent
Collected data will include:
Epidemiologic risk factors: age, sex, diabetes, hypertension, dyslipidemia, metabolic syndrome, renal insufficiency, smoking, physical activity, weight, comorbidities
Laboratory markers: LDL, HDL, cholesterol, lipoprotein A, triglycerides, CKD-EPI, sedimentation rate, fibrinogen, INR (Quick test), APTT
Diagnostics:
All patients will undergo non-contrast brain CT. Carotid stenosis will be assessed by CT angiography performed within 3 months prior to surgery. In addition to stenosis severity, the degree of calcification will be classified as:
No calcification
Minimal
Partially calcified
Pronounced
Severe/unable to evaluate
Other vascular pathology will also be recorded. Follow-up imaging will be performed at 1 month and 1 year postoperatively. CT findings will be assessed by two independent reviewers.
Surgical Technique:
All patients will receive mono- or dual antiplatelet therapy, and 5,000 IU of heparin will be administered intraoperatively. Surgery may be performed under general anesthesia with electrophysiological monitoring or under local anesthesia, based on the surgeon's preference.
A longitudinal incision will be made anterior to the sternocleidomastoid muscle. The common carotid artery and its branches will be dissected and clamped. The internal carotid artery will be clamped distal to the most significant stenosis, as identified on preoperative CTA. The surgeon will incise through the tunica adventitia and media to expose and excise the atherosclerotic plaque. Any residual fragments will be removed, and the arterial wall will be closed using 6/0 suture.
Follow-Up:
Patients will continue on mono- or dual antiplatelet therapy. Mandatory follow-up CT angiography will be performed at 30 days and1 year. During follow-up, the following will be evaluated:
CTA findings
Overall patient condition
Incidence of ischemic stroke (iCMP), TIA, myocardial infarction, and death
Outcomes:
Primary Outcome:
Restenosis ≥50% at 12 months
Secondary Outcomes:
Residual stenosis ≥50% at 30 days
iCMP/TIA/death/MI
Change in modified Rankin Scale (mRS)
Timeline:
All participating centers (ÚVN, ČB, ÚNL, Poruba, Plzeň, Liberec, Zlín, Olomouc, Hradec Králové, Fifejdy, Ostrava) together treat approximately 600-700 patients annually.
An estimated 350 patients will be enrolled within 6 months. By the end of 2026, 300 patients will be included (expected dropout: 50).
This will allow evaluation of:
Secondary outcomes in all 300 patients
Primary outcome in approximately 8 out of 26 centers (those with complete 12-month data)
Ethical Approval:
All participating centers have received approval from their respective institutional ethics committees.
Funding:
This study is conducted without external financial support.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients after carotid endarterectomy | – | –Included paitnets with sign informed consent after carotid endarterectomy |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients who undergo carotid endarterectomy for carotid artery stenosis with primary suture.
Key inclusion criteria (1 listed)
- Patients without matching any of exclusion criteria who underwent cartotid endarterectomy
Key exclusion criteria (8 listed)
- Age ≤18 or ≥90 years
- Previous endarterectomy or stenting
- Unsuitable vascular anatomy
- High perioperative risk
- Contralateral cranial nerve X or XII palsy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Restenosis ≥50% at 12 months
Time frame: 12 months
Restenosis ≥50% at 12 months
3 secondary outcomes
Restenosis ≥50%
Time frame: 30 days
iCMP/TIA/death/MI
Time frame: 1 year
Change in modified Rankin Scale (mRS)
Time frame: 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2025.
- Individual participant dataSharing planned: Yes. Epidemiologic risk factors: age, sex, diabetes, hypertension, dyslipidemia, metabolic syndrome, renal insufficiency, smoking, physical activity, weight, comorbidities Laboratory markers: LDL, HDL, cholesterol, lipoprotein A, triglycerides, CKD-EPI, sedimentation rate, fibrinogen, INR (Quick test), APTT
Related trials for Carotid Arteriosclerosis
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Not yet recruitingObservational study
PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)
Carotid Atherosclerosis, Carotid Artery Stenosis Asymptomatic
Recruiting
Isometric Resistance Exercise on Accelerated Atherosclerosis in Hypertension
Atherosclerosis Cardiovascular Disease
Recruiting
Predicting High-Risk Carotid Plaque: Integrating radioMics and biomEchanics
Carotid Artery, Carotid Arteriosclerosis
Not yet recruiting
Effects of Rosa Roxburghii Tratt Freeze-Dried Powder on Carotid Atherosclerotic Plaques: A Real-World Study
Carotid Artery Plaques, Atherosclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Carotid Arteriosclerosis and Carotid Stenosis, run by Charles University, Czech Republic at 1 site in Czechia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Czechia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact norbert Svoboda, MD (+420973202963, norbert.svoboda@uvn.cz), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Restenosis ≥50% at 12 months (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2025.